182 related articles for article (PubMed ID: 34406596)
1. Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis.
Li M; Zhou X
Inflammopharmacology; 2021 Oct; 29(5):1371-1378. PubMed ID: 34406596
[TBL] [Abstract][Full Text] [Related]
2. Blood long non-coding RNA intersectin 1-2 is highly expressed and links with increased Th17 cells, inflammation, multiple organ dysfunction, and mortality risk in sepsis patients.
Huang Q; Wang Y; He F
J Clin Lab Anal; 2022 Apr; 36(4):e24330. PubMed ID: 35243686
[TBL] [Abstract][Full Text] [Related]
3. The correlation of long non-coding RNA intersectin 1-2 with disease risk, disease severity, inflammation, and prognosis of acute ischemic stroke.
Zhang Y; Niu C
J Clin Lab Anal; 2020 Feb; 34(2):e23053. PubMed ID: 31647141
[TBL] [Abstract][Full Text] [Related]
4. MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.
Yuan J; Xiang L; Wang F; Zhang L; Liu G; Chang X; Zhang A; Tao Y
J Clin Lab Anal; 2022 Jul; 36(7):e24472. PubMed ID: 35622982
[TBL] [Abstract][Full Text] [Related]
5. JKAP serves as a potential biomarker for the evaluation of inflammatory condition, disease activity, and treatment response to TNF inhibitor in ankylosing spondylitis patients.
Zhou X; Li M
Mod Rheumatol; 2022 Apr; 32(3):613-618. PubMed ID: 34918117
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal variation of circulating Inc-ITSN1-2: A novel biomarker reflecting disease severity, inflammation, recurrence, and death risk in acute ischemic stroke patients.
Wang G; Zhou Y; Zhong T; Song A; Xue Q
J Clin Lab Anal; 2022 Jun; 36(6):e24468. PubMed ID: 35500161
[TBL] [Abstract][Full Text] [Related]
7. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
8. PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis.
Zhang Q; Jin D; Mou X; Ye H
J Clin Lab Anal; 2022 Mar; 36(3):e24267. PubMed ID: 35104386
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of long non-coding RNA intersectin 1-2 for occurrence and in-hospital mortality of severe acute pancreatitis.
Li J; Bu X; Chen X; Xiong P; Chen Z; Yu L
J Clin Lab Anal; 2020 May; 34(5):e23170. PubMed ID: 31880027
[TBL] [Abstract][Full Text] [Related]
10. Lnc-ITSN1-2, Derived From RNA Sequencing, Correlates With Increased Disease Risk, Activity and Promotes CD4
Nie J; Zhao Q
Front Immunol; 2020; 11():852. PubMed ID: 32547537
[No Abstract] [Full Text] [Related]
11. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
[TBL] [Abstract][Full Text] [Related]
13. LncRNA ITSN1-2 knockdown inhibits OGD/R-induced inflammation and apoptosis in mouse hippocampal neurons via sponging miR-195-5p.
Zhu F; Luo E; Yi F; Xiong J; Huang C; Li R
Neuroreport; 2021 Nov; 32(16):1325-1334. PubMed ID: 34554938
[TBL] [Abstract][Full Text] [Related]
14. Serum interα-trypsin inhibitor heavy chain H4 may be an anti-inflammatory marker reflecting disease risk, activity and treatment outcome of ankylosing spondylitis.
Sun Z; Zhang Y; Zhou H; Li J; Zhou Y; Wang L
Scand J Clin Lab Invest; 2023 Dec; 83(8):540-547. PubMed ID: 38156824
[TBL] [Abstract][Full Text] [Related]
15. Predictive Values of Blood Type I and Type II Interferon Production for Disease Activity and Clinical Response to TNF-α Blocking Therapy in Patients with Ankylosing Spondylitis.
Hu Y; Lou B; Jiang Z; Yu C
Tohoku J Exp Med; 2023 Jul; 260(3):263-271. PubMed ID: 37081619
[TBL] [Abstract][Full Text] [Related]
16. Circulating lncRNA ITSN1-2 is upregulated, and its high expression correlates with increased disease severity, elevated inflammation, and poor survival in sepsis patients.
Zeng Q; Wu J; Yang S
J Clin Lab Anal; 2019 May; 33(4):e22836. PubMed ID: 30803045
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
van der Heijde D; Schiff MH; Sieper J; Kivitz AJ; Wong RL; Kupper H; Dijkmans BA; Mease PJ; Davis JC;
Ann Rheum Dis; 2009 Jun; 68(6):922-9. PubMed ID: 18701556
[TBL] [Abstract][Full Text] [Related]
19. Aquaporin-1 expression as an indicator in evaluating the efficacy of meloxicam in the treatment of ankylosing spondylitis: A comparative study.
Pan JE; Xiong FL; Chen G; Zhang ZW; Xu YJ
Biomed Pharmacother; 2017 Nov; 95():1549-1555. PubMed ID: 28950654
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
